BostonGene Validates Multimodal RNA-DNA Tumor Assay in Landmark Study Across 2,200 Cancer Samples
核心洞察
BostonGene (搜索) published clinical validation of its Tumor Portrait (搜索)™ assay in Communications Medicine, demonstrating regulatory-grade performance across more than 2,200 tumor samples with 98% clinical actionability.
The multimodal platform integrates DNA and RNA sequencing into a single test, providing comprehensive tumor profiling including genetic alterations, immune signatures, and tumor microenvironment analysis.
The CLIA, CAP, and New York State Department of Health-approved assay aims to enhance patient stratification and predictive biomarker discovery for precision oncology drug development.
BostonGene (搜索) has published clinical and analytical validation data for its multimodal tumor profiling platform in Communications Medicine, a Nature portfolio journal, marking a significant advancement in precision oncology diagnostics. The study validates the company's Tumor Portrait (搜索)™ assay across more than 2,200 tumor samples, demonstrating regulatory-grade performance and high clinical utility for drug development applications.
Comprehensive Multimodal Tumor Analysis
The Tumor Portrait (搜索)™ assay represents a breakthrough in cancer diagnostics by integrating DNA and RNA sequencing into a single end-to-end test. This multimodal approach delivers comprehensive tumor characterization, including genetic alterations, gene fusions, immune signatures, tumor microenvironment profiles, and AI-based predictive classifications from a single tumor sample.
The platform has received regulatory approval under CLIA, CAP, and the New York State Department of Health, establishing its credentials for clinical use. The validation study demonstrates the assay's ability to provide clinically actionable information in 98% of tested cases, with high reproducibility across diverse tumor types.
Clinical Performance and Technical Validation
The study details the implementation of a highly stable clinical RNA-seq protocol designed for ready-to-use clinical settings. Testing across the large cohort of over 2,200 tumors confirmed the platform's robust performance characteristics, including advanced detection capabilities for various molecular alterations and immune-related biomarkers.
"Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development," said Alexander Bagaev, PhD, Chief Product Officer at BostonGene (搜索). "By combining DNA and RNA sequencing in one assay, our platform enables deeper biological understanding of the tumor microenvironment and genetics, smarter patient selection and more confident, data-driven decisions throughout the drug development lifecycle."
Impact on Drug Development and Patient Care
The validated platform addresses critical needs in oncology drug development by enhancing patient stratification, enabling predictive biomarker discovery, and improving clinical trial enrollment strategies. These capabilities are designed to reduce risks associated with drug development while improving clinical trial success rates.
BostonGene (搜索)'s AI-powered platform integrates advanced molecular and immune profiling with clinical data to generate actionable insights for trial design and patient selection optimization. The company's diagnostic and treatment recommendation solutions are already being used in clinical settings to personalize cancer care and guide therapy decisions.
The validation study establishes what Bagaev describes as "a new benchmark for translational research and diagnostic innovation," positioning the platform as a foundation for precision oncology applications and therapeutic development acceleration.